Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917319 | 0.91 | PTK2 (0.45) | PTK2PTK2BPDE5A | |
| SCHEMBL4918965 | 0.87 | PTK2 (0.50) | PTK2PDE5A | |
| SCHEMBL4917809 | 0.87 | ALDH1A1 (0.46) | PTK2PDE5A | |
| SCHEMBL4919702 | 0.86 | PDE5A (0.42) | PTK2PDE5A | |
| SCHEMBL4916374 | 0.85 | PDE5A (0.50) | PTK2PDE5A | |
| SCHEMBL4922248 | 0.85 | PTK2 (0.43) | PTK2PDE5A | |
| SCHEMBL4912787 | 0.84 | PTK2 (0.51) | PTK2PTK2BPDE5A | |
| SCHEMBL4909992 | 0.84 | PDE5A (0.43) | PTK2PDE5A | |
| SCHEMBL4914819 | 0.84 | PDE5A (0.44) | PTK2PDE5A | |
| SCHEMBL4917738 | 0.82 | MAPT (0.46) | PTK2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | PTK2 1036/4885PTK2B 468/4885PDE5A 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.